Literature DB >> 28487307

Aripiprazole-induced hypersensitivity pneumonitis.

Kulothungan Gunasekaran1, Swetha Murthi2, Jeffrey Jennings3, Nazir Lone4.   

Abstract

Aripiprazole is an atypical antipsychotic agent commonly used in the management of schizophrenia. Aripiprazole has not been reported to have an association with interstitial lung disease. We describe a case of a 36-year-old woman who began to experience respiratory issues shortly after starting aripiprazole and presented to us 4 years later with progressive exertional shortness of breath. High-resolution CT of the chest showed a bilateral ground glass pattern. Video-assisted thoracoscopy with biopsy revealed alveolar septal thickening and an inflammatory infiltrate composed mainly of lymphocytes, suggestive of chronic hypersensitivity pneumonitis. After discontinuing aripiprazole and initiating prednisolone therapy, the patient's pulmonary symptoms improved. This case highlights that aripiprazole can cause hypersensitivity pneumonitis in susceptible individuals. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  exposures; interstitial lung disease; psychiatry (drugs and medicines); unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2017        PMID: 28487307      PMCID: PMC5614109          DOI: 10.1136/bcr-2017-219929

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Hypersensitivity pneumonitis associated with temozolomide.

Authors:  L Guilleminault; P Carré; P Diot
Journal:  Eur Respir J       Date:  2009-08       Impact factor: 16.671

Review 2.  Aripiprazole: a review of its use in the management of schizophrenia in adults.

Authors:  Jamie D Croxtall
Journal:  CNS Drugs       Date:  2012-02-01       Impact factor: 5.749

3.  Aripiprazole induced non-cardiogenic pulmonary edema: a case report.

Authors:  Mustafa Cetin; Mustafa Celik; Musa Cakıcı; Mustafa Polat; Arif Suner
Journal:  Turk Psikiyatri Derg       Date:  2014

4.  Rituximab-induced hypersensitivity pneumonitis.

Authors:  Adriano R Tonelli; Richard Lottenberg; Robert W Allan; P S Sriram
Journal:  Respiration       Date:  2008-10-09       Impact factor: 3.580

5.  Pulmonary fibrosis associated with psychotropic drug therapy: a case report.

Authors:  Clare Thornton; Toby M Maher; David Hansell; Andrew G Nicholson; Athol U Wells
Journal:  J Med Case Rep       Date:  2009-11-16

Review 6.  Aripiprazole-induced hiccups: a case report.

Authors:  Prasenjit Ray; Mohammad Zia Ul Haq; S Haque Nizamie
Journal:  Gen Hosp Psychiatry       Date:  2008-10-28       Impact factor: 3.238

7.  Drug induced interstitial lung disease.

Authors:  Martin Schwaiblmair; Werner Behr; Thomas Haeckel; Bruno Märkl; Wolfgang Foerg; Thomas Berghaus
Journal:  Open Respir Med J       Date:  2012-07-27

8.  A case of venlafaxine-induced interstitial lung disease.

Authors:  Serim Oh; Seung-Ick Cha; Hyera Kim; Minjung Kim; Sun Ha Choi; Hyewon Seo; Tae-In Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-08-29

9.  Management of hypersensivity pneumonitis.

Authors:  Ioana O Agache; Liliana Rogozea
Journal:  Clin Transl Allergy       Date:  2013-02-04       Impact factor: 5.871

10.  Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report.

Authors:  Camille Sibertin-Blanc; Emmanuelle Norguet; Muriel Duluc; Guillaume Louis; Jean-François Seitz; Laetitia Dahan
Journal:  BMC Res Notes       Date:  2013-11-18
View more
  2 in total

Review 1.  Radiation-Induced Lung Injury-Current Perspectives and Management.

Authors:  Mandeep Singh Rahi; Jay Parekh; Prachi Pednekar; Gaurav Parmar; Soniya Abraham; Samar Nasir; Rajamurugan Subramaniyam; Gini Priyadharshini Jeyashanmugaraja; Kulothungan Gunasekaran
Journal:  Clin Pract       Date:  2021-07-01

2.  Aripiprazole-induced Hepatitis: A Case Report.

Authors:  Lígia Castanheira; Elsa Fernandes; Pedro Levy; Ricardo Coentre
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-11-20       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.